tiprankstipranks
Stocks
Top Analyst Stocks
Popular
Top Smart Score Stocks
Popular
Top Insiders StocksTop Gainers/ Losers/ Active StocksMost Visited WebsitesDividend StocksAI StocksLargest Companies by Market Cap
ETFs
Top ETFs by Upside
New
Top ETFs by Smart ScoreTop Gainers/ Losers/ Active ETFs
Crypto
Bitcoin
Popular
Ethereum
Commodities
Gold
New
Options
Unusual Options Activity
Popular
Currency
EUR/USD
Pro Newsletters
Smart Investor
Popular
Research Tools
Stock ScreenerETF Screener
Popular
Trending StocksDaily Analyst RatingsCompare StocksCompare ETFsPenny Stock ScreenerTechnical Analysis ScreenerDaily Insider Trading Tracker
Calendars
Earnings CalendarDividend CalendarEconomic CalendarIPO CalendarStock SplitsStock BuybacksMarket Holidays
Calculators
Dividend CalculatorDividend Yield CalculatorOptions Profit Calculator
Economic Indicators
Inflation RateUnemployment Rate
Dividend CenterBest Dividend Stocks
Popular
Best High Yield Dividend StocksDividend AristocratsDividend Stock Comparison
New
Dividend CalculatorDividend Returns ComparisonDividend Calendar
My ExpertsTop AnalystsTop Financial BloggersTop-Performing Corporate InsidersTop Hedge Fund ManagersTop Research FirmsTop Individual Investors
Personal Finance CenterMortgagesLoansInvesting & RetirementSpending & Savings
Calculators
401k Retirement CalculatorMortgage Calculator
Popular
Compound Interest CalculatorDollar Cost Averaging
New
Student Loan CalculatorAuto Loan Calculator
Education
How To Use TipRanksTipRanks LabsWebinar CenterGlossaryFAQs
About Us
About TipRanksContact UsCareersReviewsMobile APP
Working with TipRanks
Enterprise SolutionsTop Online BrokersBecome an Affiliate
Follow Us
NewsTrendingPortfolio
TOOLS
Portfolio
Watchlist
Top Insiders Stocks
Popular
Top Stocks
Popular
Top ETFs
Top Smart Score Stocks
Popular
Earnings
STOCKS
SPY
QQQ
AAPL
NVDA
TSLA
AMZN
BABA
Stocks
Top Analyst Stocks
Popular
Top Smart Score Stocks
Popular
Top Insiders Stocks
Top Gainers/ Losers/ Active Stocks
Most Visited Websites
Dividend Stocks
AI Stocks
Largest Companies by Market Cap
ETFs
ETF Center
Top ETFs by Upside
New
Top ETFs by Smart Score
Top Gainers/ Losers/ Active ETFs
Options
Options Market Overview
Unusual Options Activity
Popular
Most Active Options
Options Volume Leaders
Commodities
Gold
New
Crypto
Crypto Center
Bitcoin
Popular
Ethereum
Currency
Currency Center
EUR/USD
Pro Newsletters
Smart Investor
Popular
Research Tools
Stock Screener
ETF Screener
Popular
Trending Stocks
Daily Analyst Ratings
Compare Stocks
Compare ETFs
Penny Stock Screener
Technical Analysis Screener
Daily Insider Trading Tracker
Calendars
Earnings Calendar
Dividend Calendar
Economic Calendar
IPO Calendar
Stock Splits
Stock Buybacks
Market Holidays
Economic Indicators
Economic Indicators Center
Inflation Rate
Unemployment Rate
Federal Funds Rate
Calculators
Dividend Calculator
Dividend Yield Calculator
Options Profit Calculator
Dollar Cost Averaging
New
Dividend Center
Best Dividend Stocks
Popular
Best High Yield Dividend Stocks
Dividend Aristocrats
Dividend Stock Comparison
New
Dividend Calculator
Dividend Returns Comparison
Dividend Calendar
Top Analysts
Top Financial Bloggers
Top-Performing Corporate Insiders
Top Hedge Fund Managers
Top Research Firms
Top Individual Investors
News
Portfolio
Personal Finance Center
Mortgages
Loans
Investing & Retirement
Spending & Savings
Calculators
Compound Interest Calculator
New
Mortgage Calculator
Popular
Auto Loan Calculator
Student Loan Calculator
401k Retirement Calculator
Enterprise Solutions
Plans & Pricing
Education
How To Use TipRanks
TipRanks Labs
Webinar Center
Glossary
FAQs
About Us
About TipRanks
Contact Us
Careers
Reviews
Mobile APP
Working with TipRanks
Enterprise Solutions
Top Online Brokers
Become an Affiliate
Follow Us

KYMR Stock Latest News

Kymera Therapeutics director sells $17.3M in common stock
The FlyKymera Therapeutics director sells $17.3M in common stock
7d ago
KYMR
Kymera Therapeutics price target raised to $36 from $31 at B. Riley
PremiumThe Fly
Kymera Therapeutics price target raised to $36 from $31 at B. Riley
8d ago
KYMR
Kymera Therapeutics to Present in Fireside Chat at the UBS Virtual Targeted Protein Degradation Day
PremiumPress Releases
Kymera Therapeutics to Present in Fireside Chat at the UBS Virtual Targeted Protein Degradation Day
8d ago
KYMR
Kymera Therapeutics jumps 10% to $35.09 after expanding phase 2 trials
PremiumThe Fly
Kymera Therapeutics jumps 10% to $35.09 after expanding phase 2 trials
8d ago
SNY
KYMR
Kymera Therapeutics Advances with Sanofi in Phase 2 Trials
PremiumCompany Announcements
Kymera Therapeutics Advances with Sanofi in Phase 2 Trials
8d ago
8K
KYMR
Kymera expands HS and AD Phase 2 trials following review
PremiumThe FlyKymera expands HS and AD Phase 2 trials following review
8d ago
SNY
KYMR
Kymera Announces Expansion of KT-474 (SAR444656) HS and AD Phase 2 Studies Following Interim Review of Safety and Efficacy
PremiumPress Releases
Kymera Announces Expansion of KT-474 (SAR444656) HS and AD Phase 2 Studies Following Interim Review of Safety and Efficacy
8d ago
KYMR
Kymera Therapeutics Shareholders Approve Key Governance Proposals
PremiumCompany Announcements
Kymera Therapeutics Shareholders Approve Key Governance Proposals
26d ago
8K
KYMR
Kymera Therapeutics presents clinical data from Phase 1 trial of KT-333
PremiumThe Fly
Kymera Therapeutics presents clinical data from Phase 1 trial of KT-333
1M ago
KYMR
Kymera Therapeutics Presents New Clinical Data from the Ongoing Phase 1 Trial of STAT3 Degrader KT-333 at EHA Annual Meeting
PremiumPress Releases
Kymera Therapeutics Presents New Clinical Data from the Ongoing Phase 1 Trial of STAT3 Degrader KT-333 at EHA Annual Meeting
1M ago
KYMR
Kymera Therapeutics participates in a conference call with JPMorgan
PremiumThe Fly
Kymera Therapeutics participates in a conference call with JPMorgan
1M ago
KYMR
Kymera Therapeutics participates in a conference call with JPMorgan
PremiumThe Fly
Kymera Therapeutics participates in a conference call with JPMorgan
1M ago
KYMR
Kymera Therapeutics participates in a conference call with JPMorgan
PremiumThe FlyKymera Therapeutics participates in a conference call with JPMorgan
1M ago
KYMR
Kymera presents clinical data from ongoing Phase 1 trial of MDM2 Degrader KT-253
PremiumThe Fly
Kymera presents clinical data from ongoing Phase 1 trial of MDM2 Degrader KT-253
1M ago
KYMR
Kymera Therapeutics Presents New Clinical Data from Ongoing Phase 1 Trial of MDM2 Degrader KT-253 at ASCO Annual Meeting
PremiumPress Releases
Kymera Therapeutics Presents New Clinical Data from Ongoing Phase 1 Trial of MDM2 Degrader KT-253 at ASCO Annual Meeting
2M ago
KYMR
Kymera Therapeutics to Participate in Upcoming June Investor Conferences
PremiumPress Releases
Kymera Therapeutics to Participate in Upcoming June Investor Conferences
2M ago
KYMR
Kymera Therapeutics to present new clinical data for KT-253 at ASCO
PremiumThe Fly
Kymera Therapeutics to present new clinical data for KT-253 at ASCO
2M ago
KYMR
Kymera Therapeutics Presents New Preclinical Data for KT-621, a First-In-Class, Oral STAT6 Degrader at the ATS Annual Meeting
PremiumPress Releases
Kymera Therapeutics Presents New Preclinical Data for KT-621, a First-In-Class, Oral STAT6 Degrader at the ATS Annual Meeting
2M ago
KYMR
Kymera Therapeutics presents preclinical data fror KT-621
PremiumThe Fly
Kymera Therapeutics presents preclinical data fror KT-621
2M ago
KYMR
Kymera Therapeutics to present data from ongoing Phase 1 trial of KT-333
PremiumThe FlyKymera Therapeutics to present data from ongoing Phase 1 trial of KT-333
2M ago
KYMR
Kymera Therapeutics to Present New Clinical Data from the Ongoing Phase 1 Trial of STAT3 Degrader KT-333 at EHA Annual Meeting
PremiumPress Releases
Kymera Therapeutics to Present New Clinical Data from the Ongoing Phase 1 Trial of STAT3 Degrader KT-333 at EHA Annual Meeting
2M ago
KYMR
Kymera Therapeutics price target lowered to $52 from $53 at Oppenheimer
PremiumThe Fly
Kymera Therapeutics price target lowered to $52 from $53 at Oppenheimer
2M ago
KYMR

Trending

Name
Price
Price Change
SPX
S&P 500
DJIA
Dow Jones
NDX
Nasdaq 100
More Trending Stocks >